Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 10 September 2013 | By Alexander Gaffney, RAC,
The US Food and Drug Administration (FDA) has released a new final guidance document intended to assist sponsors in determining whether a research study involving human subjects may be conducted without first filing an investigational new drug (IND) application with US regulators.
In recent months, FDA has proven to be somewhat amicable to the idea of extending enforcement discretion-that is, expressing that it won't punish an entity-when human research is conducted without an IND, which are reviewed by FDA to ensure that human research is safe and likely to benefit patients.
The most notable expression of that policy has come with respect to fecal microbiota transplants (FMT), an emerging treatment option for persons afflicted with infections of Clostridium difficile (C. diff), a hardy bacteria that is often difficult to treat with antibiotics. FMT transplants work by taking desirable bacteria from a healthy person's bowels and then implanting the (usually processed) bacteria into the bowels of the patient affected by C. diff, which then have the chance to overpower the existing infection.
FDA had originally said it would require an IND to be submitted for the procedure, but later tempered this position after receiving withering criticism from patient advocates who said the change would make conducting FMTs onerous and unaffordable.
"Some health care providers have stated that applying IND requirements will make FMT unavailable and have suggested that an alternative regulatory approach is needed to ensure the widespread availability of FMT for individuals with C. difficile infection unresponsive to standard therapies," FDA explained. "The agency acknowledges these concerns and intends to exercise enforcement discretion regarding the IND requirements for the use of FMT to treat C. difficile infection not responding to standard therapies provided the treating physician obtains adequate informed consent from the patient or his or her legally authorized representative for the use of FMT products."
But the FMT approach is just one instance of when an IND won't be required-what about other disease areas? Could they stand to benefit from a similar enforcement approach as well?
FDA's new final guidance document, Investigational New Drug Applications (INDs) - Determining Whether Human Research Studies Can Be Conducted Without an IND, is intended to clarify when an IND isn't required as well as "specific situations" that could confuse sponsors of human research.
The guidance notes a number of specific instances in which it may not be clear if use of an FDA-regulated product might trigger a required IND filing. Those include:
Generally, any investigation involving the administration of a drug to a human is subject to an IND per 21 CFR 312. That requirement is in effect if all three of the following conditions exist simultaneously:
It is important to note that the term "drug" can also mean "biological products," such as allergenic extracts, gene therapy products, monoclonal antibodies and more.
But the meat of the guidance comes in its fourth section, in which FDA describes which policies are exempt from the IND requirements of 21 CFR 320.31(b).
For example, research involving already-marketed drug products can be exempt, provided the research meets the following conditions:
The key here, FDA explains, is that any changes be "low risk modifications" that keep patients safe and are considered in light of the inherent risks and complexities of the drug product.
" For example, minor variations to solid oral dosage forms, such as changing the color, scoring, or capsule size of the marketed dosage form for blinding purposes, would generally be low risk, provided the changes did not involve major manufacturing or formulation changes," FDA wrote.
Bioequivalence and bioavailability studies can also be exempt from IND submissions. Such exemptions may be granted if:
Other examples of potential IND exemptions include: radioactive isotopes, cold isotopes, endogenous compounds, live organisms, cosmetics, dietary supplements and conventional foods.
The guidance also includes a multi-page frequently asked questions (FAQ) section. Perhaps the most notable of the questions: Even if a study enrolls only a small number of subjects, that does not exempt it from IND requirements.
"The number of subjects enrolled has no bearing on whether the study is subject to the IND regulations," FDA explained. "The definition of clinical investigation specifically includes studies with as few as one subject."
The full guidance is available on FDA's website.
Investigational New Drug Applications (INDs) - Determining Whether Human Research Studies Can Be Conducted Without an IND
Federal Register
Tags: Human Research, IND, Latest News, studies, guidance, clinical trials
Regulatory Focus newsletters
All the biggest regulatory news and happenings.